MedTrace Logo

Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation

NCT01435525 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 369

Last updated 2014-04-16

No results posted yet for this study

Summary

The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy in patients given triple therapy for Helicobacter pylori eradication with Nexium + amoxicillin (AMPC) + clarithromycin (CAM), or Nexium + AMPC + metronidazole (MNZ) in usual post-marketing use.

Conditions

  • Gastric Ulcer
  • Duodenal Ulcer
  • Gastric Mucosa-associated Lymphoid Tissue (MALT)
  • Lymphoma Idiopathic Thrombocytopenic Purpura
  • Early Gastric Cancer

Sponsors & Collaborators

Principal Investigators

  • Shigeru Yoshida, MD · AstraZeneca

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01435525 on ClinicalTrials.gov